Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA)

By sjmartinez • April 4, 2025

Rikhi R, Haidar A, Bhatia HS, Beam K, McParland J, Kazibwe R, Chevli P, Schaich CL, Sanghavi M, Shapiro MD. Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2025 Mar 27;404:119179. doi: 10.1016/j.atherosclerosis.2025.119179. Epub ahead of print. PMID: 40179714.

Tags: cardiovascular risk, coronary heart disease, diabetes, Hematology/Oncology, lipoprotein(a), primary prevention, Publications

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan[...]